Locations:
Search IconSearch
March 19, 2018/Cancer

New AJCC TNM Edition More Accurately Predicts Recurrence in Pulmonary Carcinoid Tumors

Turn to 8th edition for better correlation

PrimaryPulmonaryCarcinoid

By Josephine Dermawan, MD, PhD, and Carol Farver, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Pulmonary carcinoid tumors are the uncommon, clinically indolent relative of non-small cell lung cancer (NSCLC). Because current lung cancer staging guidelines are largely based on data from NSCLC, which is vastly more common, using American Joint Committee on Cancer (AJCC) TNM staging to predict long-term recurrence and survival for carcinoid tumors is unclear at best and controversial for most. Our research team sought to offer some clarity to this controversy through a single-institution study that correlates pathologic stage from both the 7th and 8th editions of the Staging Manual with clinical outcomes for carcinoid tumors. We presented our findings at the 2018 Annual Meeting of the United States and Canadian Academy of Pathology.

We identified 217 surgical lung resection cases from 1995-2015 with a diagnosis of primary lung carcinoid tumors and staged them according to both the 7th and 8th editions of the AJCC TNM Classification of Lung Tumors. We also collected clinical data, including demographics, smoking history, recurrence and survival. Patients with concurrent or preexisting malignancies and/or positive resection margins were excluded.

Of the 181 cases available for clinical follow-up, 16 experienced recurrence (9 percent) and five (3 percent) died with metastatic carcinoid tumor. Atypical carcinoid tumors were more significantly likely to recur (log-rank P < 0.0001). Because the 8th edition of TNM places more emphasis on tumor size, staging based on this edition was more likely than the 7th edition to predict outcomes in our study (P < 0.0001 vs P = 0.0026). Procedure type and smoking history did not correlate with outcomes.

Advertisement

Based on our study, we recommend the criteria in the 8th edition of AJCC’s TNM Classification of Lung Tumors for stating primary lung carcinoid tumors. Classifying carcinoid tumors based on typical versus atypical histology types, which is based on mitotic figure counts on histology, is still the best predictor of tumor recurrence. We are currently examining the applicability of the ki67 proliferative index as another tool for classifying this tumor and predicting tumor recurrence.

Advertisement

Related Articles

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Squamous cell carcinoma
June 2, 2025/Cancer/News & Insight
Adjuvant Immunotherapy in High-Risk Cutaneous Squamous Cell Carcinoma

Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit

Ad